Press Releases

Showing 106-140 of 181


2012

September

September 13

Abbott Recognized for Leading Citizenship Performance for Eighth Consecutive Year by Dow Jones Sustainability Indexes

September 12

According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives

September 6

Abbott to Collaborate with Astellas in CMV Vaccine Trial
 

August

August 30

Abbott's HUMIRA® (Adalimumab) Approved in Europe for Expanded Treatment of Crohn’s Disease (CD)

August 28

Abbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels

August 20

Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent

August 13

Public Voting Now Open to Help Grant Two $20,000 Abbott CFCareForward Scholarships to Students with Cystic Fibrosis

August 7

Abbott's Omnilink Elite® Vascular Balloon-Expandable Stent System Receives FDA Approval for Treatment of Iliac Artery Disease
 

July

July 30

Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Non-radiographic Axial Spondyloarthritis (nr-axSpA)

July 18

Abbott Reports Strong Second Quarter Results

July 16

The Abbott Fund Announces $1 Million Partnership with the Secretary's International Fund for Women and Girls to Empower Women in Burma

July 13

Abbott Focuses on the Importance of Information Management and Automation at the American Association for Clinical Chemistry Lab Expo

July 11

Abbott Introduces OneLab, a Novel Integrated Web-Based Software Platform to Manage the Vast Amounts of Information Flowing Through the Lab

July 10

Abbott Announces New Test for the Management of Patients with Diabetes

July 6

Seven Pharmaceutical Companies Join Academic Researchers to Speed TB Drug Discovery

July 3

Abbott Receives FDA Approval for Healon EndoCoat Protective Gel for Cataract Surgery
 

June

June 27

Abbott Hosts Conference Call for Second-Quarter Earnings

June 27

Abbott, The Abbott Fund and Direct Relief International Reach Key HIV Testing Milestones: 20 Million Tests Provided Over 10 Years, and More Than 150,000 HIV Cases Prevented in Children

June 26

Abbott Introduces New Limited Ingredient Nutrition Bar – Perfectly Simple™ by ZonePerfect®

June 25

Abbott Receives Positive Opinion for HUMIRA® in Non-radiographic Axial Spondyloarthritis from EMA's CHMP

June 20

Abbott Again Named One of the Best Workplaces in Europe

June 18

Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease

June 12

Abbott Expands CFChef Program in 2012 for People Affected by Cystic Fibrosis

June 8

Abbott Declares 354th Consecutive Quarterly Dividend

June 6

Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-radiographic Axial Spondyloarthritis

June 6

Abbott Presents Phase 3 Study Results for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Peripheral Spondyloarthritis

June 6

Abbott Announces 10-Year Data Evaluating HUMIRA® (Adalimumab) for Patients with Long-Standing Moderate-to-Severe Rheumatoid Arthritis

June 5

Abbott Introduces Ensure Clear™ to Help Adults Fill Dietary Gap

June 5

Abbott Announces Initiation of Phase 3 Study of Elagolix in Patients with Endometriosis

June 1

Abbott Again Recognized as One of the 'Best Places to Work in Industry' by The Scientist Magazine
 

May

May 29

Abbott to Present at Goldman Sachs 33rd Annual Global Healthcare Conference

May 29

Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (Europe)

May 29

Abbott to Present Wide Range of Investigational Efficacy, Safety and Health Outcomes Data on HUMIRA® (Adalimumab) at the Annual Meeting of the European League Against Rheumatism - (U.S.)

May 16

Abbott Launches PediaSure SideKicks® Clear for Picky Eaters

May 15

Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe for Minimum Three-Month Duration of Dual Anti-Platelet Therapy